Dr. Donington is a Professor in Surgery and chief of the section of Thoracic Surgery. Her clinical and interests focus on the diagnosis and treatment of non-small cell lung cancer. Areas of expertise include the use of multimodality therapy for locally advanced lung cancer, treatment options for high-risk patients with early stage lung cancer and lung cancer in women. She is the surgical chair for the thoracic malignancy group of NRG Oncology Group, council member for the Western Thoracic Surgical Association, and immediate past-president of the New York Society for Thoracic Surgery, and the Women in Thoracic Surgery.
NYU
New York, NY
MS - Clinical Research
2010
Mayo Hospital and Clinics
Rochester, MN
- Cardiothoracic Surgery
2002
Georgetown University
Washington, DC
- General Surgery
1999
NIH/NCI/Surgery Branch
Bethesda, MD
- Surgical Oncology
1996
Rush University
Chicago, IL
MD - Medicine
1992
University of Michigan
Ann Arbor, MI
BS - Biology
1987
Implementing a Frailty-Specific Postoperative Order Set to Improve Postoperative Outcomes in Frail Adults After Elective Thoracic Surgery.
Implementing a Frailty-Specific Postoperative Order Set to Improve Postoperative Outcomes in Frail Adults After Elective Thoracic Surgery. J Nurs Care Qual. 2024 Jun 26.
PMID: 38936412
Cost effectiveness of commercial portable ex vivo lung perfusion at a low-volume US lung transplant center.
Cost effectiveness of commercial portable ex vivo lung perfusion at a low-volume US lung transplant center. Artif Organs. 2024 Jun 24.
PMID: 38924545
American Radium Society Appropriate Use Criteria for Unresectable Locally Advanced Non-Small Cell Lung Cancer.
American Radium Society Appropriate Use Criteria for Unresectable Locally Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2024 Jun 01; 10(6):799-806.
PMID: 38602670
Pack-Year Smoking History: An Inadequate and Biased Measure to Determine Lung Cancer Screening Eligibility.
Pack-Year Smoking History: An Inadequate and Biased Measure to Determine Lung Cancer Screening Eligibility. J Clin Oncol. 2024 Jun 10; 42(17):2026-2037.
PMID: 38537159
Real-World Neoadjuvant Treatment Patterns and Outcomes in Resected Non-Small-Cell Lung Cancer.
Real-World Neoadjuvant Treatment Patterns and Outcomes in Resected Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2024 Jul; 25(5):440-448.
PMID: 38627155
Event-free survival as a predictor of overall survival and recurrence burden of patients with non-small cell lung cancer receiving neoadjuvant therapy.
Event-free survival as a predictor of overall survival and recurrence burden of patients with non-small cell lung cancer receiving neoadjuvant therapy. J Thorac Cardiovasc Surg. 2023 Dec 12.
PMID: 38092284
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revisions of the T-Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer.
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revisions of the T-Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2024 May; 19(5):749-765.
PMID: 38070600
Racial differences in phenotypic frailty assessment among general thoracic surgery patients.
Racial differences in phenotypic frailty assessment among general thoracic surgery patients. JTCVS Open. 2023 Dec; 16:1049-1062.
PMID: 38204700
What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?
What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer? Ther Adv Med Oncol. 2023; 15:17588359231198446.
PMID: 37720499
Restructuring lung cancer care to accelerate diagnosis and treatment in patients vulnerable to healthcare disparities using an innovative care model.
Restructuring lung cancer care to accelerate diagnosis and treatment in patients vulnerable to healthcare disparities using an innovative care model. MethodsX. 2023 Dec; 11:102338.
PMID: 37701734